Home » Policy & Publications » Expert Groups » UK & International Health Policy and Drug Safety

UK & International Health Policy and Drug Safety

Please note that this expert group was retired in June 2025. Below is an archive page for the group.

The ‘UK & International Health Policy and Drug Safety’ group considered government and regulatory consultations, legislation, bills and white papers etc. related to all aspects of healthcare where pharmaceutical R&D, regulatory affairs and medical affairs are impacted. The group’s remit covered all aspects of pharmaceutical medicine – from clinical pharmacology, through phase 1-4 clinical trials, regulatory interactions, to post-licensing monitoring, and drug safety and pharmacovigilance.

Some of the group's outputs

Consultation: NHS Change – The 10-Year Health Plan for England

Date: November 2024

Alongside all FPM’s Expert Groups and Committees, the Oncology Expert Group responded to a consultation on NHS Change – The 10-Year Health Plan for England.

Read FPM’s response here:

FPM Response to Consultation on the NHS 10 Year Health Plan for England

House of Lords Science and Technology Committee inquiry into delivering a UK science and technology strategy – Call for Evidence

Date: Submitted March 2022

The House of Lords Science and Technology Committee is conducting an inquiry into the Government’s plans to deliver a UK science and technology strategy. The inquiry will consider what such a strategy should look like and how the UK’s research and innovation system can deliver it. The Health Policy expert group spearheaded FPM’s response to this Call for Evidence which also included input from across FPM’s other expert groups. The Committee has now stopped accepting evidence and has published its report ‘”Science and technology superpower”: more than a slogan?’.

Read the report.